Vical Inc. entered into a research collaboration agreement with AnGes MG Inc.

Under the agreement, AnGes agreed to provide funding for the program up to a specified limit, and Vical agreed to conduct certain preclinical research related to a development program targeting chronic hepatitis B.

In exchange for the payment, AnGes will receive an option to negotiate exclusive rights in Japan related to the program.

The companies also agreed to share the costs of prosecuting and maintaining intellectual property rights arising from the research program after such costs reach a specified limit.